Geographic variations as large as 47% for medical imaging have been identified in the first systematic study of its kind, performed by researchers at Thomas Jefferson University in Philadelphia. A comparison of changes in geographic utilization rates from 1997 to 2002 reveals that cardiologists have higher growth rates for Medicare-reimbursed imaging than radiologists or other physicians who perform medical imaging, said Dr. Vijay Rao, radiology director at Jefferson.
Geographic variations as large as 47% for medical imaging have been identified in the first systematic study of its kind, performed by researchers at Thomas Jefferson University in Philadelphia. A comparison of changes in geographic utilization rates from 1997 to 2002 reveals that cardiologists have higher growth rates for Medicare-reimbursed imaging than radiologists or other physicians who perform medical imaging, said Dr. Vijay Rao, radiology director at Jefferson.
"In all of the 10 regions of the country, the utilization growth rate is higher - in fact, it is much higher - among cardiologists compared to radiologists," she said.
Data were drawn from the Medicare Part B fee-for-service statistics for 1997 and 2002 for regions surrounding Atlanta, Boston, Chicago, Dallas, Denver, Kansas City, New York, Philadelphia, San Francisco, and Seattle.
Outpatient imaging utilization rates for Medicare beneficiaries in 2002 ranged from 3959 per thousand in Atlanta to a low of 2694 per thousand in Seattle.
The rates attributed to radiologists varied 39% across the country. They were highest in Philadelphia, where radiologists performed 2511 exams per 1000 population in 2002. They were lowest in San Francisco, where the utilization rate was 1803 per thousand.
In contrast, the utilization rates for imaging procedures performed by cardiologists varied by 91% from 323 to 617 per thousand from region to region, Rao said. For other physicians, the highs and lows were 941 and 568, respectively.
More analysis is needed to understand the reasons for regional variations in the use of diagnostic imaging, she said.
"We don't know why there is such a big variation. It could be access. It could relate to the amount of disease, or it could relate to the population," Rao said.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.